Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments

• Published in: Radiation oncology (London, England) England), 2012-08, Vol.7 (1), p.145-145, Article 145
• Main Authors: Scorsetti, Marta, Alongi, Filippo, Fogliata, Antonella, Pentimalli, Sara, Navarria, Pierina, Lobefalo, Francesca, Garcia-Etienne, Carlos, Clivio, Alessandro, Cozzi, Luca, Mancosu, Pietro, Nicolini, Giorgia, Vanetti, Eugenio, Eboli, Marco, Rossetti, Carlo, Rubino, Arianna, Sagona, Andrea, Arcangeli, Stefano, Gatzemeier, Wolfgang, Masci, Giovanna, Torrisi, Rosalba, Testori, Alberto, Alloisio, Marco, Santoro, Armando, Tinterri, Corrado
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Breast cancer; Breast Neoplasms - pathology; Breast Neoplasms - radiotherapy; Cancer therapies; Carcinoma, Ductal, Breast - pathology; Carcinoma, Ductal, Breast - radiotherapy; Carcinoma, Lobular - pathology; Carcinoma, Lobular - radiotherapy; Care and treatment; Chemotherapy; Dose Fractionation; Feasibility Studies; Female; Follow-Up Studies; Fractionation; Health aspects; Humans; Hypofractionation; Lumpectomy; Methods; Middle Aged; Neoplasm Grading; Neoplasm Staging; Oncology; Patient outcomes; Prognosis; Radiation; Radiation Injuries - etiology; Radiation therapy; Radiotherapy; Radiotherapy, Adjuvant; Radiotherapy, Intensity-Modulated - adverse effects; Simultaneous integrated boost; Skin; Study Protocol; Surgery; Thoracic surgery; Toxicity; Volumetric modulated arc therapy
• ISSN: 1748-717X; 1748-717X
• DOI: 10.1186/1748-717X-7-145

To report results in terms of feasibility and early toxicity of hypofractionated simultaneous integrated boost (SIB) approach with Volumetric Modulated Arc Therapy (VMAT) as adjuvant treatment after breast-conserving surgery. Between September 2010 and May 2011, 50 consecutive patients presenting early-stage breast cancer were submitted to adjuvant radiotherapy with SIB-VMAT approach using RapidArc in our Institution (Istituto Clinico Humanitas ICH). Three out of 50 patients were irradiated bilaterally (53 tumours in 50 patients). All patients were enrolled in a phase I-II trial approved by the ICH ethical committee. All 50 patients enrolled in the study underwent VMAT-SIB technique to irradiate the whole breast with concomitant boost irradiation of the tumor bed. Doses to whole breast and surgical bed were 40.5 Gy and 48 Gy respectively, delivered in 15 fractions over 3 weeks. Skin toxicities were recorded during and after treatment according to RTOG acute radiation morbidity scoring criteria with a median follow-up of 12 months (range 8-16). Cosmetic outcomes were assessed as excellent/good or fair/poor. The median age of the population was 68 years (range 36-88). According to AJCC staging system, 38 breast lesions were classified as pT1, and 15 as pT2; 49 cases were assessed as N0 and 4 as N1. The maximum acute skin toxicity by the end of treatment was Grade 0 in 20/50 patients, Grade 1 in 32/50, Grade 2 in 0 and Grade 3 in 1/50 (one of the 3 cases of bilateral breast irradiation). No Grade 4 toxicities were observed. All Grade 1 toxicities had resolved within 3 weeks. No significant differences in cosmetic scores on baseline assessment vs. 3 months and 6 months after the treatment were observed: all patients were scored as excellent/good (50/50) compared with baseline; no fair/poor judgment was recorded. No other toxicities or local failures were recorded during follow-up. The 3-week course of postoperative radiation using VMAT with SIB showed to be feasible and was associated with acceptable acute skin toxicity profile. Long-term follow-up data are needed to assess late toxicity and clinical outcomes.